
Kiniksa Pharmaceuticals Q4 Loss Narrower Than Expected, Revenues Beat Estimates: A Detailed Analysis
Kiniksa Pharmaceuticals’ Q3 Loss: A Surprise Deviation from Expectations In a recent financial announcement, Kiniksa Pharmaceuticals, Ltd. (KNSA) reported a quarterly loss of $0.12 per share, which was a significant departure from the Zacks Consensus Estimate of a loss of $0.06 per share for the third quarter of 2022. This unexpected outcome has raised some…